See more : Healthlead Public Company Limited (HL.BK) Income Statement Analysis – Financial Results
Complete financial analysis of Lyell Immunopharma, Inc. (LYEL) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Lyell Immunopharma, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Berenson Acquisition Corp. I (BACA) Income Statement Analysis – Financial Results
- Polaris Holdings Co., Ltd. (3010.T) Income Statement Analysis – Financial Results
- Venus Acquisition Corporation (VENAU) Income Statement Analysis – Financial Results
- Digital Information Technologies Corporation (3916.T) Income Statement Analysis – Financial Results
- BAIC Motor Corporation Limited (1958.HK) Income Statement Analysis – Financial Results
Lyell Immunopharma, Inc. (LYEL)
About Lyell Immunopharma, Inc.
Lyell Immunopharma, Inc., a T cell reprogramming company, engages in developing T cell therapies for patients with solid tumors. The company develops therapies using technology platforms, such as Gen-R, an ex vivo genetic reprogramming technology to overcome T cell exhaustion; and Epi-R, an ex vivo epigenetic reprogramming technology to generate population of T cells with durable stemness. Its pipeline includes LYL797, a T cell product candidate for the treatment of non-small cell lung cancer and triple negative breast cancers; LYL845, that targets multiple solid tumors; and NY-ESO-1 for synovial sarcoma and other solid tumor indications. The company entered into research and development collaboration and license agreement with GlaxoSmithKline for NY-ESO-1 program. Lyell Immunopharma, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 130.00K | 84.68M | 10.65M | 7.76M | 657.00K |
| Cost of Revenue | 0.00 | 16.47M | 14.54M | 7.48M | 0.00 |
| Gross Profit | 130.00K | 68.22M | -3.89M | 281.00K | 657.00K |
| Gross Profit Ratio | 100.00% | 80.55% | -36.48% | 3.62% | 100.00% |
| Research & Development | 182.95M | 159.19M | 138.69M | 182.24M | 63.60M |
| General & Administrative | 66.98M | 117.31M | 89.06M | 46.88M | 39.15M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 66.98M | 117.31M | 89.06M | 46.88M | 39.15M |
| Other Expenses | -2.79M | 1.89M | -2.32M | -9.43M | -35.41M |
| Operating Expenses | 247.14M | 276.50M | 225.43M | 219.69M | 102.75M |
| Cost & Expenses | 247.14M | 276.50M | 225.43M | 219.69M | 102.75M |
| Interest Income | 23.45M | 7.05M | 1.17M | 5.94M | 8.12M |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 20.25M | 16.47M | 14.54M | 7.48M | 4.38M |
| EBITDA | -226.76M | -166.65M | -199.94M | -207.64M | -100.83M |
| EBITDA Ratio | -174,429.23% | -194.96% | -1,546.53% | -2,677.19% | -15,347.49% |
| Operating Income | -247.01M | -183.12M | -214.78M | -211.94M | -102.09M |
| Operating Income Ratio | -190,006.15% | -216.24% | -2,016.68% | -2,732.56% | -15,538.66% |
| Total Other Income/Expenses | 12.38M | 3.84M | -36.65M | 7.47M | -27.29M |
| Income Before Tax | -234.63M | -183.12M | -250.22M | -204.47M | -129.38M |
| Income Before Tax Ratio | -180,486.15% | -216.24% | -2,349.47% | -2,636.31% | -19,692.09% |
| Income Tax Expense | 0.00 | -178.36M | 35.28M | -5.94M | -8.12M |
| Net Income | -234.63M | -4.75M | -285.50M | -198.53M | -121.26M |
| Net Income Ratio | -180,486.15% | -5.61% | -2,680.76% | -2,559.73% | -18,456.01% |
| EPS | -0.93 | -0.02 | -1.18 | -0.81 | -0.49 |
| EPS Diluted | -0.93 | -0.02 | -1.18 | -0.81 | -0.49 |
| Weighted Avg Shares Out | 250.98M | 247.08M | 242.74M | 246.58M | 246.58M |
| Weighted Avg Shares Out (Dil) | 250.98M | 247.08M | 242.74M | 246.58M | 246.58M |
3 Biotech Stocks to Sell in August Before They Crash & Burn
For investors, one of the most attractive aspects of biotech stocks is their ability to increase in value in a short period of time quickly. After all, it only takes one major breakthrough in clinical trials or a Food and...
Lyell Immunopharma Reports Dose-dependent Clinical Activity from Phase 1 Trial of LYL797, a ROR1-targeted CAR-T Cell Product Candidate Enhanced with its Proprietary Anti-exhaustion Technology
SOUTH SAN FRANCISCO, Calif., June 26, 2024 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical‑stage T-cell reprogramming company advancing a diverse pipeline of cell therapies for patients with solid tumors, today announced initial clinical and translational data from...
Lyell Immunopharma to Participate in the Goldman Sachs Global Healthcare Conference
SOUTH SAN FRANCISCO, Calif., June 03, 2024 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical‑stage T-cell reprogramming company advancing a diverse pipeline of cell therapies for patients with solid tumors, today announced that members of its senior management...
Lyell Immunopharma to Participate in BofA Securities Health Care Conference
SOUTH SAN FRANCISCO, Calif., May 07, 2024 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical‑stage T-cell reprogramming company advancing a diverse pipeline of cell therapies for patients with solid tumors, today announced that members of its senior management...
Lyell Immunopharma Reports Business Highlights and Financial Results for the First Quarter 2024
SOUTH SAN FRANCISCO, Calif., May 06, 2024 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical‑stage T-cell reprogramming company advancing a diverse pipeline of cell therapies for patients with solid tumors today reported financial results and business highlights for...
Lyell Immunopharma: Testing The T-Cell Thesis With 2 Upcoming Data Catalysts
Lyell Immunopharma, Inc.'s stock price has risen over 20% YTD and over 45% in the past 12 months. The company focuses on T-cell therapies for solid tumors and has two clinical-stage assets. Lyell has upcoming data catalysts, with Phase 1...
Lyell Immunopharma (LYEL) Is Up 28.45% in One Week: What You Should Know
Does Lyell Immunopharma (LYEL) have what it takes to be a top stock pick for momentum investors? Let's find out.
Lyell Immunopharma Announces the Acceptance of Three Abstracts for Presentation at 2024 AACR Annual Meeting
SOUTH SAN FRANCISCO, Calif., March 05, 2024 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical‑stage T-cell reprogramming company advancing a diverse pipeline of cell therapies for patients with solid tumors, announced that three abstracts of new nonclinical data...
Lyell Immunopharma Reports Business Highlights and Financial Results for the Fourth Quarter and Full Year 2023
SOUTH SAN FRANCISCO, Calif., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical‑stage T-cell reprogramming company advancing a diverse pipeline of cell therapies for patients with solid tumors today reported financial results and business highlights for...
Lyell Immunopharma Announces Participation in March Investor Conferences
SOUTH SAN FRANCISCO, Calif., Feb. 26, 2024 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical‑stage T-cell reprogramming company advancing a diverse pipeline of cell therapies for patients with solid tumors, announced today that members of its senior management...
Source: https://incomestatements.info
Category: Stock Reports